The robustness of our data for tafasitamab continued to generate a lot of interest from clinicians and we will be very well represented at upcoming virtual scientific or medical conferences like ASH or EHA and ASCO.Let's now take a closer look at the most important financial figures of MorphoSys for the first quarter 2020 that have been significantly impacted by the successful closure of the company's collaboration and licensing agreement with Incyte.